Tag Archives: Emerging Companies

Propel Small Business Innovation through Tax Reform

Jeffery_Hatfield copy

As CEO of an emerging clinical-stage biotech company, I lose over $10 million each year. Over the lifetime of my company, I have lost over $100 million. But constantly losing money in an effort to advance discoveries should not overshadow the real lifeblood of biotechnology, which is the reward of seeing patients treated, lives saved, and families healed. Some of the biggest challenges companies like mine face include high research and production costs, coupled with Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The Pivotal Role the Public Market Plays in Financing R&D

KennethMoch-Chimerix

Growing innovators are the heart of our industry. Biotech small businesses face a dual struggle – the daily challenge of running a growing company combined with the roadblocks intrinsic to groundbreaking scientific advancement. Innovative companies must overcome capital formation barriers in order to fund their next generation R&D.  The financing challenges that emerging biotechs face are unique, but we have the potential to save lives and treat patients in desperate need of hope. Today, I Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Crowdfunding Goes Viral

Crowdfunding

Is crowdfunding a viable source of capital for biotech companies? μBiome thinks so; they are a startup biotech company that raised $351,193. They asked for $100,000. That’s right; over three times their goal. “[Crowdfunding for biotech] is an idea whose time has come,” says μBiome’s CEO Jessica Richman. “The fact that we did it is proof of that. We’re the first ones but there will be lots of others.” Is there a way that crowdfunding could help Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Small Biotech Companies and China: 5 Keys to Success

BIO CEO

Big pharmaceutical countries aren’t the only ones investing in China. Emerging and mid-sized biotech companies are also exploring ways to enter China’s lucrative market and maximize their investment in the country. With limited resources, how can smaller companies operate efficiently and give Chinese patients access to their innovative products? A panel of experts explored these questions at the 2013 BIO CEO & Investor Conference. Jimmy Zhang from Merck moderated a panel including: Friedhelm Blobel, PhD, President, CEO, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotech Hall of Fame: Interview with Biotech’s First Investment Banker

Biotech Hall of Fame

Earlier this week, I had the opportunity to discuss biotech’s storied history with Fred Frank, one of the industry’s greatest luminaries, on what we can learn from the past to help shape the future. Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,